Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis

Figure 7

ECHO cardiographic representation of effects of aprepitant or fasudil treatment in viral-myocarditis. A representative ECHO reading from (a) uninfected mouse, (b) EMCV-infected mouse, (c) uninfected mouse with aprepitant pretreatment, (d) EMCV-infected mouse with aprepitant pretreatment, (e) uninfected mouse with aprepitant posttreatment, (f) EMCV-infected mouse with aprepitant posttreatment, (g) uninfected mouse with fasudil pretreatment, (h) EMCV-infected mouse with fasudil pretreatment, (i) uninfected mouse with fasudil posttreatment, and (j) EMCV-infected mouse with fasudil posttreatment.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)